Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share By
The Present and Future Disease Burden of Hepatitis C Virus Infections With Today's Treatment Paradigm - Volume 3 Publisher Pubmed



Sibley A1 ; Han KH2 ; Abourached A3 ; Lesmana LA4, 5 ; Makara M6 ; Jafri W7 ; Salupere R8 ; Assiri AM9 ; Goldis A10 ; Abaalkhail F11 ; Abbas Z12 ; Abdou A13 ; Al Braiki F14 ; Al Hosani F15 Show All Authors
Authors
  1. Sibley A1
  2. Han KH2
  3. Abourached A3
  4. Lesmana LA4, 5
  5. Makara M6
  6. Jafri W7
  7. Salupere R8
  8. Assiri AM9
  9. Goldis A10
  10. Abaalkhail F11
  11. Abbas Z12
  12. Abdou A13
  13. Al Braiki F14
  14. Al Hosani F15
  15. Al Jaberi K16
  16. Al Khatry M17
  17. Al Mulla MA15
  18. Al Quraishi H18
  19. Al Rifai A19
  20. Al Serkal Y20
  21. Alam A21
  22. Alavian SM22, 23
  23. Alashgar HI24
  24. Alawadhi S13
  25. Aldabal L25
  26. Aldins P26
  27. Alfaleh FZ27
  28. Alghamdi AS28
  29. Alhakeem R9
  30. Aljumah AA29
  31. Almessabi A14
  32. Alqutub AN28
  33. Alswat KA30
  34. Altraif I29
  35. Alzaabi M31
  36. Andrea N32
  37. Babatin MA28
  38. Baqir A33
  39. Barakat MT34
  40. Bergmann OM35
  41. Bizri AR36
  42. Blach S1
  43. Chaudhry A37
  44. Choi MS38
  45. Diab T39
  46. Djauzi S4
  47. El Hassan ES13
  48. El Khoury S40
  49. Estes C1
  50. Fakhry S41
  51. Farooqi JI42, 43
  52. Fridjonsdottir H44
  53. Gani RA4
  54. Ghafoor Khan A45
  55. Gheorghe L46
  56. Gottfredsson M47
  57. Gregorcic S48
  58. Gunter J1
  59. Hajarizadeh B49, 50
  60. Hamid S51
  61. Hasan I4
  62. Hashim A52
  63. Horvath G53
  64. Hunyady B54, 55
  65. Husni R56
  66. Jeruma A57, 58
  67. Jonasson JG59, 60
  68. Karlsdottir B61
  69. Kim DY2
  70. Kim YS62
  71. Koutoubi Z63
  72. Liakina V64, 65
  73. Lim YS66
  74. Love A47, 67
  75. Maimets M8
  76. Malekzadeh R68
  77. Maticic M48
  78. Memon MS69
  79. Merat S68
  80. Mokhbat JE70
  81. Mourad FH71
  82. Muljono DH72, 73
  83. Nawaz A74
  84. Nugrahini N75
  85. Olafsson S35
  86. Priohutomo S76
  87. Qureshi H77
  88. Rassam P40
  89. Razavi H1
  90. Razavishearer D1
  91. Razavishearer K1
  92. Rozentale B57, 58
  93. Sadik M69
  94. Saeed K78
  95. Salamat A79
  96. Sanai FM27
  97. Sanityoso Sulaiman A4
  98. Sayegh RA80
  99. Sharara AI71
  100. Siddiq M81, 82, 83
  101. Siddiqui AM83
  102. Sigmundsdottir G84, 85
  103. Sigurdardottir B61
  104. Speiciene D64
  105. Sulaiman A4, 86
  106. Sultan MA86
  107. Taha M87
  108. Tanaka J88
  109. Tarifi H89
  110. Tayyab G90, 91, 92
  111. Tolmane I57, 59
  112. Ud Din M92
  113. Umar M93, 94, 95
  114. Valantinas J64
  115. Videcnikzorman J48
  116. Yaghi C80, 82
  117. Yunihastuti E95
  118. Yusuf MA96
  119. Zuberi BF97
  120. Schmelzer JD1

Source: Journal of Viral Hepatitis Published:2015


Abstract

The total number, morbidity and mortality attributed to viraemic hepatitis C virus (HCV) infections change over time making it difficult to compare reported estimates from different years. Models were developed for 15 countries to quantify and characterize the viraemic population and forecast the changes in the infected population and the corresponding disease burden from 2014 to 2030. With the exception of Iceland, Iran, Latvia and Pakistan, the total number of viraemic HCV infections is expected to decline from 2014 to 2030, but the associated morbidity and mortality are expected to increase in all countries except for Japan and South Korea. In the latter two countries, mortality due to an ageing population will drive down prevalence, morbidity and mortality. On the other hand, both countries have already experienced a rapid increase in HCV-related mortality and morbidity. HCV-related morbidity and mortality are projected to increase between 2014 and 2030 in all other countries as result of an ageing HCV-infected population. Thus, although the total number of HCV countries is expected to decline in most countries studied, the associated disease burden is expected to increase. The current treatment paradigm is inadequate if large reductions in HCV-related morbidity and mortality are to be achieved. © 2015 John Wiley & Sons Ltd.
Other Related Docs